Your browser doesn't support javascript.
loading
Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54].
Mir, Maria Carmen; Marchioni, Michele; Zargar, Homi; Zargar-Shoshtari, K; Fairey, A S; Mertens, Laura S; Dinney, C P; Krabbe, L M; Cookson, M S; Jacobsen, N E; Griffin, J; Montgomery, J S; Vasdev, N; Yu, E Y; Xylinas, E; McGrath, J S; Kassouf, W; Dall'Era, M A; Sridhar, S S; Aning, J; Shariat, S F; Wright, J L; Thorpe, A C; Morgan, T M; Holzbeierlein, J M; Bivalacqua, T J; North, S; Barocas, D A; Lotan, Y; Grivas, P; Stephenson, A J; Shah, J B; van Rhijn, B W; Spiess, P E; Daneshmand, S; Black, P C.
Afiliación
  • Mir MC; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Fundacion Instituto Valenciano Oncologia, Valencia, Spain. Electronic address: mirmare@yahoo.es.
  • Marchioni M; Departmentof Medical, Oral and Biotechnological Sciences, Urology Unit, University "G. d'Annunzio", Chieti-Pescara, Italy.
  • Zargar H; Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
  • Zargar-Shoshtari K; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Fairey AS; University of Alberta, Edmonton, Alberta, Canada.
  • Mertens LS; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Dinney CP; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.
  • Krabbe LM; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, University of Münster, Münster, Germany.
  • Cookson MS; Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
  • Jacobsen NE; University of Alberta, Edmonton, Alberta, Canada.
  • Griffin J; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Montgomery JS; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
  • Vasdev N; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.
  • Yu EY; Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Xylinas E; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY, USA; Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France.
  • McGrath JS; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK.
  • Kassouf W; Department of Surgery (Division of Urology), McGill University Health Center, Montreal, Canada.
  • Dall'Era MA; Department of Urology, University of California at Davis, Davis Medical Center, Sacramento, CA, USA.
  • Sridhar SS; Princess Margaret Hospital, Toronto, Ontario, Canada.
  • Aning J; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK.
  • Shariat SF; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY, USA; Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; UT Southwestern, Dallas, TX, USA; Charles University, Prag, Czech Republic; University of Jordan, Amman, Jord
  • Wright JL; Department of Urology, University of Washington, Seattle, WA, USA.
  • Thorpe AC; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.
  • Morgan TM; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
  • Holzbeierlein JM; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Bivalacqua TJ; Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • North S; Cross Cancer Institute, Edmonton, AB, Canada; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
  • Barocas DA; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Grivas P; Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Stephenson AJ; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, RUSH University, Chicago, IL, USA.
  • Shah JB; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.
  • van Rhijn BW; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Spiess PE; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Daneshmand S; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
  • Black PC; Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Eur Urol Focus ; 8(5): 1559, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35181282
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur Urol Focus Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur Urol Focus Año: 2022 Tipo del documento: Article